EMIS – Bio-Tech Comeback Kid. Up 89% Yesterday since StockGuru Spotlight. See Our Top Five Picks of the Week.

EMIS – Bio-Tech Comeback Kid.  Up 89% Yesterday since StockGuru Spotlight.  See Our Top Five Picks of the Week.

StockGuru Spotlight October 28, 2010

BULM, UNRH, SDRG, CNYC, CSBQ, AAIR, SCLW

Dear Members:

EMIS – StockGuru Spotlights Come Back Kid of the week!  We focused on this stock the day it jumped off the cliff.  Now it is making a slow and steady comeback.  Read more about this amazing company.  As you know, at StockGuru we have a strong admiration for Bio-tech.  This week Novartis Pharma AG (“Novartis”) provided Emisphere with information regarding the First Interpretable Results of the two-year Phase III Study 2301 in osteoarthritis conducted by its license partner Nordic Bioscience with oral calcitonin (SMC021) and the stock started a relentless upward climb.

Be sure to check out StockGuru’s Top Five Picks this week.  I know, there are six Companies in the top five.  There are just too many great companies out there.

EMIS — COME BACK KID — Up 89%
$75 M Market Cap

EMIS News Release EMIS StockGuru

Emisphere Technologies, Inc. (OTCBB:EMIS ) announced this week that Novartis Pharma AG (“Novartis”) provided Emisphere with information regarding the First Interpretable Results of the two-year Phase III Study 2301 in osteoarthritis conducted by its license partner Nordic Bioscience with oral calcitonin (SMC021).  Then

The recently completed study assesses the safety and efficacy of oral calcitonin in the treatment of osteoarthritis of the knee and had three co-primary endpoints. Novartis informed Emisphere that preliminary analysis of the data from this study shows that the endpoint for the first of three co-primary endpoints, joint space width narrowing, was not met. Novartis also informed Emisphere that results regarding the other two co-primary endpoints indicated clinical efficacy related to symptom modification (WOMAC scales: pain, function). In addition, according to Novartis, MRI analyses suggested an effect on cartilage.

Nordic Bioscience and Novartis have indicated that they are going to continue to work together to further analyze and evaluate the results of this study. The second two-year Phase III Study 2302, which also assesses safety and efficacy of oral calcitonin of patients with osteoarthritis of the knee, is currently ongoing. Additionally, the Phase III clinical program of oral calcitonin in osteoporosis continues.

About Emisphere Technologies, Inc.

Emisphere is a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules or nutritional supplements using its Eligen(R) Technology. These molecules and compounds could be currently available or in development. Such molecules are usually delivered by injection; in many cases, their benefits are limited due to poor bioavailability, slow on-set of action or variable absorption. The Eligen(R) Technology can be applied to the oral route of administration as well as other delivery pathways, such as buccal, rectal, inhalation, intra-vaginal or transdermal. The company’s website is: www.emisphere.com.

Get On Board – the Stock Guru Trading Way – Top Five Picks This Week

Pick Date Pick Price Company Close Up Market Cap
18-Jun-10 $       1.35 WOVT $       2.03 50% $  119.90
15-Oct-10 $       1.13 ISCO $       1.60 42% $  114.74
14-Jun-10 $       0.43 FEEC $       0.57 33% $  105.82
29-Jul-10 $       1.11 DAFX $       1.70 53% $  100.06
15-Sep-10 $       0.96 PVCT $       1.24 29% $    98.26
7-Oct-10 $       3.50 SOKF $       4.35 24% $    87.93

We are NOT compensated in any way for these Spotlight Picks. If we decide to include a pick for which we are compensated you will be clearly informed. StockGuru Spotlights While you can never catch the exact high StockGuru shows you the potential when you learn to trade the StockGuru Way. We look at the news that moves the stocks — good and bad. StockGuru brings you trading news you can use and meaningful trends.

Our StockGuru Spotlight Picks Are Published Before the Open Each Morning StockGuru Spotlights are featured on our web site. We have an RSS feed and an exclusive twitter feed for StockGuru Spotlights. We also issue press releases on the StockGuru Spotlights; you can see proof positive our notice to you is truly an advanced notice. StockGuru is not not jumping on these after they move. Here is the link to BOOKMARK for Spotlights: http://www.stockguru.com/tag/spotlight Don’t Miss Our on Spotlight Stocks! It is critical to catch these alerts in the morning prior to the market open. I have been asked several times recently how to get them.

IMPORTANT: Bookmark this link: http://www.stockguru.com/tag/spotlight Check This Link Every Morning for New Spotlight Stocks All of these are date and time stamped so you know what is current today. You can also just go to STOCKGURU.COM and look for the link in the top navigation for “StockGuru Spotlight.” You can also put the RSS link into your RSS reader, such as my favorite “Google Reader.”

There are countless programs that make it easy to get RSS feeds on your wireless phone as well. This is foolproof BUT ONLY IF YOU CHECK YOUR RSS FEED REGULARLY! RSS link on the site. We do not yet send out Spotlight Alerts by email, in an attempt to give your email box a break. Spotlights occur several times weekly, and are released ONLY when we see a valid reason. Occasionally, our Spotlights are compensated picks, but an editorial decision is made as to whether the situation qualifies as a market sensitive pick and we ALWAYS include a disclosure prominently if we include a company for which we have been compensated in either cash or shares.

StockGuru is in its Eighth Year!

OTCBB: ZERO or STWA, Inc. Disclosure: StockGuru LLC was compensated 60,000 144 restricted common shares by the company for profile coverage. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. We currently hold no shares and have taken no additional shares, nor have we purchases any in the market. To avoid all potential conflicts of interest, we never sell shares into the open market during an active market awareness or investor relations program or during any time thereafter when our activities might impact the value of the shares. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we are not selling shares at the same time. We hold no shares and will not be receiving further compensation in shares or that is share while we are covering this company. StockGuru is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. Our contact information is Pentony Enterprises; 1601 Berwick Drive; McKinney, Texas 75070; Telephone 469-252-303

Left Menu Icon
Right Menu Icon